Summary

  • GE HealthCare has agreed to pay $945 million in cash for SOFIE Biosciences, adding 15 U.S. contract-manufacturing sites with 21 cyclotrons, plus a theranostics-focused CDMO site. The transaction has not closed; GE expects completion in the first half of 2027, subject to conditions and regulatory approvals.
  • The acquisition combines a production network, existing customer relationships and U.S. rights to Phase 3 tracer FAPI-74. None is interchangeable: a site count is not utilization, a registered clinical trial is not a result, and management’s accretion forecast is not a disclosed target-level return.
  • GE says SOFIE will continue as an independent supplier to its customers, including other radiopharmaceutical providers. That promise is central to the deal’s value: the network has to remain credible to manufacturers whose products may compete with GE’s.

Analysis

The phrase “final mile” can make a supply-chain purchase sound like a small logistics add-on. In PET radiopharmaceuticals, the last mile is part of the product. GE HealthCare says fluorine-18-labelled tracers have a 110-minute half-life. A manufacturing footprint, dispatch schedule and access to nearby customers therefore matter alongside the molecule itself. The company’s October 5 agreement to buy SOFIE Biosciences is a bet on that operating surface as much as on a pipeline.

GE disclosed a $945 million cash purchase price and expects to close in the first half of 2027, pending conditions that include regulatory approvals. It says SOFIE brings 15 U.S. contract-manufacturing sites operating 21 cyclotrons and a theranostics-focused contract-development and manufacturing site. Those figures describe a footprint, not dose output, customer utilization, route density or margin. The release gives no site-level financials, target revenue, EBITDA, contract concentration or purchase multiple. It is not possible to divide the purchase price by a reliable public operating denominator.

The network’s commercial design is unusually important because SOFIE is not described as a captive plant. GE says the company will continue to serve existing customers as an independent manufacturing partner after closing, including products from other radiopharmaceutical providers. GE also says PDx will keep working with other established contract manufacturers and serve demand through a mix of owned and partner facilities. That is a different proposition from simply moving GE’s own products in-house.

The acquired network must expand GE’s reach without making outside customers doubt whether their products, schedules or information will receive equal treatment.

That distinction has economic consequences. A site may have technical capacity yet produce little value if sponsors do not book it, if a product cannot be delivered within its usable window, or if customers shift orders because they see the new owner as a competitor. Conversely, preserving multi-client trust can make a distributed manufacturing network more valuable than the sum of its buildings and machines. The public announcement establishes management’s intention to preserve that model; it does not show how customer contracts, pricing, scheduling priorities or data controls will work after close.

FAPI-74 supplies a second source of optionality, but it is not a clinical outcome. GE already holds rights outside the United States; the acquisition adds U.S. rights to SOFIE’s Phase 3 tracer. SOFIE’s August 21 newsletter says its FAPI-GO and FAPI-PRO studies had 15 sites activated and steady patient enrollment over the preceding months. The ClinicalTrials.gov records describe Phase 3 diagnostic studies and show no posted results; their last updates were in June.

Trial registration and site activation are evidence of development activity, not evidence that the tracer improves diagnosis, has received approval, or will be reimbursed and adopted at scale.

The buyer’s results offer context, not a substitute for target economics. In the quarter ended June 30, GE reported $843 million of PDx revenue, up 15.6% year over year, and $250 million of segment EBIT, up 16.9%, with a 29.6% margin. Those are segment figures before this proposed acquisition closes; they include the existing business and do not isolate SOFIE. GE’s statement that the deal should be accretive to revenue growth, adjusted EBIT margin and adjusted EPS in its first full year of ownership remains management guidance. Without SOFIE’s standalone base and the costs of integration and expansion, investors cannot test the bridge.

The valuation question is therefore not whether GE bought “a radiopharmacy network” or “a Phase 3 asset.” It bought a package whose components have different clocks: regulatory approval for the transaction, clinical evidence for FAPI-74, customer retention for contract manufacturing, and repeated delivery performance for the sites. If one clock slips, the others may still have value, but they do not automatically compensate. The near-term business case rests on maintaining both owned capacity and trusted external partnerships while the clinical program advances.

For now, the $945 million figure prices an announced strategic acquisition, not a demonstrated return. The next useful evidence is a closing update, disclosure of how much of the footprint is active and commercially utilized, and proof that outside manufacturers continue to use SOFIE after control changes. For FAPI-74, the decisive milestones are trial results, regulatory progress and commercial terms—not the transfer of U.S. rights alone.

Sources